{"id":"NCT02105701","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)","officialTitle":"A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects Who Have Failed Prior Treatment With Pegylated Interferon and Ribavirin (P/R) With Chronic HCV GT1, GT4, and GT6 Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06-05","primaryCompletion":"2015-03-24","completion":"2015-06-19","firstPosted":"2014-04-07","resultsPosted":"2016-03-04","lastUpdate":"2021-02-05"},"enrollment":420,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Infection"],"interventions":[{"type":"DRUG","name":"Grazoprevir + Elbasvir","otherNames":["MK-5172A"]},{"type":"DRUG","name":"Ribavirin","otherNames":["RebetolÂ®"]}],"arms":[{"label":"Grazoprevir + Elbasvir 12 weeks","type":"EXPERIMENTAL"},{"label":"Grazoprevir + Elbasvir + RBV 12 weeks","type":"EXPERIMENTAL"},{"label":"Grazoprevir + Elbasvir 16 weeks","type":"EXPERIMENTAL"},{"label":"Grazoprevir + Elbasvir + RBV 16 weeks","type":"EXPERIMENTAL"}],"summary":"This is an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) with or without ribavirin (RBV) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infections who have failed prior therapy with pegylated interferon and RBV. The primary study hypothesis is that in at least one of the study arms, the percentage of participants achieving sustained viral response 12 weeks after the end of all study treatment (SVR12) will be superior to 58%.","primaryOutcome":{"measure":"Percentage of Participants Achieving Undetectable HCV RNA 12 Weeks After Completing Study Therapy (SVR12)","timeFrame":"12 weeks after the end of all study treatment (up to 28 weeks)","effectByArm":[{"arm":"Grazoprevir + Elbasvir 12 Weeks","deltaMin":92.4,"sd":null},{"arm":"Grazoprevir + Elbasvir + RBV 12 Weeks","deltaMin":94.2,"sd":null},{"arm":"Grazoprevir + Elbasvir 16 Weeks","deltaMin":92.4,"sd":null},{"arm":"Grazoprevir + Elbasvir + RBV 16 Weeks","deltaMin":98.1,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.001"},{"comp":"OG001","p":"<0.001"},{"comp":"OG002","p":"<0.001"},{"comp":"OG003","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":18},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["27720838","29461687","29404492","28193518"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":105},"commonTop":["Fatigue","Headache","Nausea","Asthenia","Accidental overdose"]}}